Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 490.35 DKK 2.86% Market Closed
Market Cap: 2.2T DKK

EV/EBITDA
Enterprise Value to EBITDA

14.4
Current
23.3
Median
12.8
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
14.4
=
Enterprise Value
2.2T DKK
/
EBITDA
155.3B DKK
Market Cap EV/EBITDA
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 14.4
US
Eli Lilly and Co
NYSE:LLY
729.6B USD 35.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
372.9B USD 12.5
CH
Roche Holding AG
SIX:ROG
213.3B CHF 9.7
CH
Novartis AG
SIX:NOVN
190.2B CHF 10.6
UK
AstraZeneca PLC
LSE:AZN
167.2B GBP 131.1
US
Merck & Co Inc
NYSE:MRK
198.7B USD 8.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
132.7B USD 7.3
FR
Sanofi SA
PAR:SAN
110.8B EUR 4.8
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
CSE:NOVO B
Average EV/EBITDA: 394.7
14.4
13%
1.1
US
Eli Lilly and Co
NYSE:LLY
35.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.1
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.6
FR
Sanofi SA
PAR:SAN
4.8
7%
0.7

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
13.1
2-Years Forward
EV/EBITDA
11.1
3-Years Forward
EV/EBITDA
9.9